Cerco Medical

CerCo Medical is a biotechnology company specializing in the production of high-purity Actinium-225 (Ac-225), a potent alpha-emitting isotope used in targeted alpha therapy (TAT) for cancer. Based in St. Louis, Missouri, the company utilizes advanced cyclotron-based production methods to provide a reliable supply of this scarce isotope to the radiopharmaceutical industry. In early 2024, CerCo Medical was acquired by Perspective Therapeutics to secure a domestic supply of Ac-225 for its pipeline of targeted radiotherapies. The company's infrastructure and expertise in isotope isolation and purification are critical for the development of next-generation oncology treatments targeting various solid tumors. By vertically integrating isotope production, CerCo Medical helps mitigate the global supply chain risks associated with rare radioactive materials.